Money Problems Push SoCal's ImmunoCellular To Suspend Trial, Seek Strategic Alternatives Post author:Sam Post published:June 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Eleven Bio Reports Fourth Quarter And Full Year 2016 Financial Results March 23, 2017 Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop February 6, 2018 AmerisourceBergen Pays $815M Cash for Drug Wholesaler H. D. Smith November 20, 2017